Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

TXG

10x Genomics Inc

Jun 18 • 04:00PM ET

34.76

+2.62 8.17 %

Healthcare • Health Information Services • USA • Mid • NASD

Peers: TWST RGEN TECH A BIO BRKR MTD DHR TMO WAT

| Held by: ARKK VTI ARKG IWM VB VBK VXF IBB IWN SCHA

Index	RUT	P/E	-	EPS (ttm)	-0.17	Insider Own	10.94%	Shs Outstand	118.91M	Perf Week	19.64%
Market Cap	4.41B	Forward P/E	-	EPS next Y	-0.64	Insider Trans	-0.94%	Shs Float	113.06M	Perf Month	55.92%
Enterprise Value	3.95B	PEG	-	EPS next Q	-0.23	Inst Own	98.62%	Short Float	14.59%	Perf Quarter	89.09%
Income	-22.66M	P/S	6.91	EPS this Y	-117.44%	Inst Trans	1.77%	Short Ratio	5.95	Perf Half Y	121.23%
Sales	638.78M	P/B	5.51	EPS next Y	15.65%	ROA	-2.36%	Short Interest	16.49M	Perf YTD	113.09%
Book/sh	6.31	P/C	8.17	EPS next 5Y	-9.01%	ROE	-2.98%	52W High	35.65 -2.50%	Perf Year	219.73%
Cash/sh	4.25	P/FCF	36.11	EPS past 3/5Y	37.90% 42.10%	ROIC	-2.56%	52W Low	10.38 234.83%	Perf 3Y	-40.19%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	7.57% 16.55%	Gross Margin	70.49%	Volatility	7.38% 8.16%	Perf 5Y	-82.12%
Dividend TTM	-	EV/Sales	6.19	EPS Y/Y TTM	86.67%	Oper. Margin	-11.70%	ATR (14)	2.22	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.42	Sales Y/Y TTM	2.26%	Profit Margin	-3.55%	RSI (14)	70.21	Recom	2.38
Dividend Gr. 3/5Y	- -	Current Ratio	5.90	EPS Q/Q	62.53%	SMA20	17.93%	Beta	2.06	Target Price	26.85
Payout	-	Debt/Eq	0.10	Sales Q/Q	-2.61%	SMA50	37.23%	Rel Volume	1.30	Prev Close	32.13
Employees	1178	LT Debt/Eq	0.09	Earnings	May 07 AMC	SMA200	81.95%	Avg Volume	2.77M	Price	34.76
IPO	Sep 12, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	63.65% 3.03%	Trades		Volume	3,607,397	Change	8.17%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-31-26	Upgrade	William Blair	Mkt Perform → Outperform
Dec-11-25	Downgrade	Citigroup	Buy → Neutral
Dec-02-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$20
Sep-11-25	Initiated	Piper Sandler	Neutral	$15
Feb-13-25	Downgrade	Leerink Partners	Outperform → Market Perform	$25 → $12
Sep-03-24	Initiated	Leerink Partners	Outperform	$35
Jul-22-24	Upgrade	Jefferies	Hold → Buy	$24
Jul-18-24	Downgrade	JP Morgan	Overweight → Neutral	$40 → $20
Jul-10-24	Downgrade	Deutsche Bank	Buy → Hold	$55 → $25
Jun-27-24	Downgrade	Wolfe Research	Outperform → Peer Perform
Jun-25-24	Downgrade	Guggenheim	Buy → Neutral
Jun-03-24	Resumed	Jefferies	Hold	$24
May-01-24	Downgrade	TD Cowen	Buy → Hold	$57 → $32
Dec-14-23	Initiated	Guggenheim	Buy	$60
Dec-13-23	Initiated	Wolfe Research	Outperform	$55
Dec-12-23	Upgrade	BofA Securities	Underperform → Neutral	$36 → $54
Jul-05-23	Resumed	JP Morgan	Overweight	$65
May-10-23	Initiated	Barclays	Overweight	$65
Mar-31-23	Initiated	Stephens	Overweight	$65
Feb-02-23	Initiated	UBS	Neutral	$50

Show Previous Ratings

Jun-17-26 09:00AM	10x Genomics and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies in Patients with Bladder Cancer (PR Newswire)
Jun-15-26 02:48PM	Cathie Wood Buys $444 Million in SpaceX, Dumps Tesla and AMD (GuruFocus.com) +11.72%
Jun-09-26 09:00AM	10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group (PR Newswire)
May-07-26 08:55PM	10x Genomics, Inc. Q1 2026 Earnings Call Summary (Moby)
04:34PM	10x Genomics: Q1 Earnings Snapshot (Associated Press)
04:05PM	Loading…
04:05PM	10x Genomics Reports First Quarter 2026 Financial Results (PR Newswire)
Apr-29-26 04:05PM	10x Genomics to Participate in the BofA Securities 2026 Healthcare Conference (PR Newswire) -5.47% +9.16%
Apr-18-26 10:00PM	10x Genomics Introduces Atera, a New Platform to Redefine How Biology is Measured and Understood (PR Newswire)
Apr-15-26 04:05PM	10x Genomics to Report First Quarter 2026 Financial Results on May 7, 2026 (PR Newswire)
Apr-09-26 06:00PM	Torex Gold Reports Q1 2026 Production Results (TMX Newsfile)
Apr-07-26 06:00PM	Torex Gold Welcomes Jacques Perron to Its Board of Directors (TMX Newsfile) +5.50%
Mar-31-26 09:32AM	Western Digital upgraded, PayPal initiated: Wall Street's top analyst calls (The Fly) +7.17%
04:00AM	Merck strikes deal with antibody discovery startup (BioPharma Dive)
Mar-25-26 07:00AM	Bioptimus Announces STELA: The World's Largest Clinically Linked Spatial Biology Atlas, alongside key partners 10x Genomics and Broad Clinical Labs (PR Newswire) +5.55%
Mar-24-26 06:00PM	Torex Gold Reports Year-End 2025 Reserves & Resources (TMX Newsfile)
08:00AM	Loading…
Mar-17-26 08:00AM	PerturbAI Launches from Stealth, Unveils the World's Largest In Vivo CRISPR Atlas (PR Newswire) +8.39%
Mar-09-26 08:52AM	Should You Buy, Hold or Sell Tempus AI Stock Heading Into 2026? (Zacks)
Mar-05-26 10:41PM	Life Sciences Tools & Services Stocks Q4 In Review: 10x Genomics (NASDAQ:TXG) Vs Peers (StockStory)
Mar-03-26 10:15AM	PacBio and DNAstack Collaborate on Global HiFi Genome Network Hub (Zacks)
Feb-19-26 04:05PM	10x Genomics to Participate in the 46th Annual TD Cowen Health Care Conference (PR Newswire)
12:38AM	5 Must-Read Analyst Questions From 10x Genomics's Q4 Earnings Call (StockStory)
Feb-18-26 09:41AM	Tempus AI Stock Before Q4 Earnings Release: To Buy or Not to Buy? (Zacks) +5.10%
Feb-13-26 11:30AM	Why Is 10x Genomics (TXG) Stock Soaring Today (StockStory)
08:30AM	10x Genomics, Inc. Q4 2025 Earnings Call Summary (Moby)
12:32AM	TXG Q4 Deep Dive: Consumables Growth, Spatial Expansion, and AI-Driven Demand Shape Outlook (StockStory)
12:04AM	10x Genomics Inc (TXG) Q4 2025 Earnings Call Highlights: Surpassing Revenue Expectations Amid ... (GuruFocus.com)
Feb-12-26 09:07PM	10x Genomics Q4 Earnings Call Highlights (MarketBeat) -8.56%
06:30PM	Compared to Estimates, 10x Genomics (TXG) Q4 Earnings: A Look at Key Metrics (Zacks)
05:30PM	10x Genomics (TXG) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
04:54PM	10x Genomics (NASDAQ:TXG) Delivers Impressive Q4 CY2025 (StockStory)
04:30PM	Loading…
04:30PM	10x Genomics: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	10x Genomics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Outlook for 2026 (PR Newswire)
Feb-10-26 10:07PM	10x Genomics (TXG) Reports Earnings Tomorrow: What To Expect (StockStory)
Feb-05-26 10:00AM	10x Genomics (TXG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks) -7.14%
Feb-04-26 09:00AM	PharosAI and 10x Genomics Partner to Transform Cancer Research with AI and Spatial Biology (PR Newswire)
Jan-30-26 02:48PM	Gold, Silver Crash Sparks Mining Meltdown: 10 Stocks Crater On Fed Warsh Shock (Benzinga)
Jan-22-26 04:05PM	10x Genomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026 (PR Newswire)
03:47AM	Zacks Industry Outlook Highlights Doximity, 10x Genomics and Omnicell (Zacks)
Jan-21-26 04:58PM	Cathie Wood Has 13 Big Ideas For 2026: Here's The Ark Invest List And Stocks To Watch (Benzinga)
09:53AM	3 Medical Info Systems Stocks to Gain From Digitization Despite Industry Woes (Zacks)
Jan-20-26 12:05AM	Cathie Wood's Ark Unleashes Cryptic ARKmoji Teasers To Showcase Its 'Big Ideas' For 2026: Can You Take A Guess At The Hidden Meaning? (Benzinga) +7.46%
Jan-19-26 01:27PM	Cathie Wood Buys AI Chips, Sells Tesla (GuruFocus.com)
Jan-18-26 11:40PM	3 Hyped Up Stocks That Concern Us (StockStory)
Jan-12-26 04:05PM	Why 10x Genomics (TXG) Shares Are Falling Today (StockStory)
09:11AM	10x Genomics Launches Study to Advance Research in Blood-Based Diagnostics for Autoimmune Disease (PR Newswire)
09:10AM	10x Genomics to Advance Research in Diagnostic Applications of Tumor Single Cell and Spatial Profiling (PR Newswire)
09:00AM	Cancer Research Institute Launches Transformative AI-Driven Immuno-Oncology Initiative Powered by 10x Genomics Technology (PR Newswire)
Jan-11-26 12:00PM	10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2025 Results (PR Newswire)
Jan-07-26 07:05AM	CareDx and 10x Genomics to Launch ImmuneScape Program - A Multiomics Research Platform to Decode Transplant Rejection and Drug Response (Business Wire)
Jan-02-26 01:45PM	10x Genomics (TXG) Stock Is Up, What You Need To Know (StockStory)
Dec-29-25 04:05PM	10x Genomics to Present at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-22-25 10:20PM	Barclays Turns More Bullish on 10x Genomics, Inc. (TXG) Despite Uneven Research Spending (Insider Monkey) +5.55%
11:56AM	10x Genomics (TXG) Stock Trades Up, Here Is Why (StockStory)
Dec-17-25 11:22AM	Tempus AI Turns Non-GAAP Profit on Surging Genomics and Data (Zacks)
Dec-16-25 09:07AM	Tempus AI Revenue Jumps 85% as Pricing Catalysts Line Up (Zacks)
Dec-15-25 11:30AM	Tempus AI Near $75 Target? Valuation, Upside and Risks (Zacks)
Dec-11-25 11:41AM	Why 10x Genomics (TXG) Stock Is Nosediving (StockStory) -5.65%
Dec-07-25 10:32PM	Life Sciences Tools & Services Stocks Q3 Earnings: 10x Genomics (NASDAQ:TXG) Firing on All Cylinders (StockStory)
Dec-02-25 09:34AM	Teradyne upgraded, Circle Internet initiated: Wall Street's top analyst calls (The Fly)
Nov-18-25 11:02PM	3 Reasons to Avoid TXG and 1 Stock to Buy Instead (StockStory)
09:00AM	New ASTRA Consortium Unites Asia-Pacific Scientists to Build Pan-Cancer Spatial Atlas Powered by 10x Genomics' Xenium (PR Newswire)
Nov-15-25 11:42PM	10x Genomics Expands Flex Lineup with High-Throughput Single-Cell Assay Launch (Insider Monkey)
Nov-13-25 12:33AM	5 Insightful Analyst Questions From 10x Genomics's Q3 Earnings Call (StockStory)
Nov-11-25 04:05PM	10x Genomics to Participate in the Wolfe Research Healthcare Conference 2025 (PR Newswire)
12:51PM	10x Genomics (TXG) Soars to New Record High on Lower Net Loss, Revenue Beat (Insider Monkey)
12:26PM	Why 10x Genomics (TXG) Stock Is Trading Up Today (StockStory)
07:29AM	Should You Buy, Hold or Sell TEM Stock Post Q3 Earnings Release? (Zacks)
Nov-07-25 04:06PM	Why 10x Genomics (TXG) Stock Is Trading Up Today (StockStory) +17.31% +12.00%
09:26AM	TXG Q3 Deep Dive: Spatial Biology and Consumables Drive Outperformance Amid Macro Uncertainty (StockStory)
06:36AM	Stock Market Today: U.S. Stock Futures Tumble After Overnight Reprieve, Extending Week-Long Tech Struggle (TheStreet)
Nov-06-25 07:00PM	Compared to Estimates, 10x Genomics (TXG) Q3 Earnings: A Look at Key Metrics (Zacks)
05:55PM	10x Genomics (TXG) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
04:57PM	10x Genomics's (NASDAQ:TXG) Q3: Strong Sales, Stock Jumps 13.1% (StockStory)
04:52PM	10x Genomics: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	10x Genomics Reports Third Quarter 2025 Financial Results (PR Newswire)
Nov-05-25 05:41AM	Qiagen inks $225M single-cell buyout as CEO prepares to step down (MedTech Dive)
Nov-04-25 10:17PM	10x Genomics Earnings: What To Look For From TXG (StockStory)
Oct-30-25 10:00AM	10x Genomics (TXG) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-29-25 01:39PM	Can Sustained Product Demand Drive HIMS Stock Before Q3 Earnings? (Zacks)
09:00AM	10x Genomics Launches the Next Generation of Chromium Flex to Empower Scientists to Massively Scale Single Cell Research (PR Newswire)
Oct-21-25 05:19AM	10x Genomics (TXG) Moves 11.1% Higher: Will This Strength Last? (Zacks)
Oct-20-25 12:30PM	10x Genomics and Anthropic Partner to Make Single Cell and Spatial Analysis More Accessible Through Claude for Life Sciences (PR Newswire) +11.07%
11:35AM	Why Is 10x Genomics (TXG) Stock Rocketing Higher Today (StockStory)
11:23AM	Zacks.com featured highlights include Red Robin Gourmet Burgers, 10x Genomics, Norwegian Cruise Line, Electromed and Analog Devices (Zacks)
10:10AM	PacBio Aims to Expand Multiomic Capabilities Via Latest Innovations (Zacks)
09:03AM	Tempus AI Stock Before Q3 Earnings Release: To Buy or Not to Buy? (Zacks)
Oct-17-25 11:05AM	5 Must-Buy Efficient Stocks to Increase Your Portfolio Returns (Zacks)
Oct-16-25 12:00PM	10x Genomics (TXG) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Oct-15-25 02:01PM	Why 10x Genomics (TXG) Stock Is Trading Up Today (StockStory)
Oct-10-25 03:51PM	10x Genomics, BioMarin Pharmaceutical, AMN Healthcare Services, Illumina, and Moderna Stocks Trade Down, What You Need To Know (StockStory)
Oct-09-25 04:05PM	10x Genomics to Report Third Quarter 2025 Financial Results on November 6, 2025 (PR Newswire)
Sep-16-25 12:33AM	3 Stocks Under $50 We Find Risky (StockStory)
Sep-12-25 02:25PM	10x Genomics (TXG) Stock Trades Down, Here Is Why (StockStory)
Sep-11-25 11:56AM	10x Genomics (TXG) Stock Is Up, What You Need To Know (StockStory)
Sep-09-25 08:44AM	TEM Q2 Revenues Soar Amid Coverage Issues: Time to Buy, Hold or Sell? (Zacks)
Aug-27-25 04:05PM	10x Genomics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference (PR Newswire)
Aug-24-25 11:34PM	Q2 Earnings Highs And Lows: 10x Genomics (NASDAQ:TXG) Vs The Rest Of The Life Sciences Tools & Services Stocks (StockStory)
Aug-22-25 12:04AM	3 Reasons TXG is Risky and 1 Stock to Buy Instead (StockStory) +9.16%
Aug-20-25 12:37AM	1 Cash-Producing Stock for Long-Term Investors and 2 We Turn Down (StockStory)
Aug-19-25 09:00AM	10x Genomics Launches Xenium Protein, Advancing Spatial Biology by Enabling Same-Cell RNA and Protein Analysis (PR Newswire)

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company's products include Single Cell Gene Expression, Immune Profiling, ATAC, and Genome. The company was founded by Serge Saxonov, Ben Hindson and Kevin D. Ness on July 2, 2012 and is headquartered in Pleasanton, CA.

Co-FounderDr. Serge Saxonov Ph.D.

Co-FounderDr. Benjamin J. Hindson Ph.D.

CFOMr. Adam S. Taich

Chief of Global OperationsMr. Jim Goodrich

Founding Scientist & CTOMr. Michael Schnall-Levin Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SULIMAN SHEHNAAZ	Director	Jun 16 '26	Sale	32.63	5,723	186,756	31,722	Jun 18 04:08 PM
Shehnaaz Suliman	Affiliate	Jun 16 '26	Proposed Sale	32.22	5,723	184,395		Jun 16 07:58 PM
Saxonov Serge	Chief Executive Officer	May 22 '26	Sale	24.44	18,175	444,224	1,149,098	May 27 05:57 PM
Saxonov Serge	Chief Executive Officer	May 26 '26	Sale	24.71	10,718	264,833	1,138,380	May 27 05:57 PM
Hindson Benjamin J.	See Remarks	May 22 '26	Sale	24.44	11,595	283,399	502,000	May 27 05:56 PM
Taich Adam	Chief Financial Officer	May 22 '26	Sale	24.44	15,098	369,018	379,898	May 27 05:55 PM
Serge Saxonov	Director, CEO	May 26 '26	Proposed Sale	23.68	40,718	964,202		May 26 04:56 PM
Saxonov Serge	Officer	May 22 '26	Proposed Sale	24.68	17,948	442,957		May 22 08:31 PM
Hindson Benjamin J.	Officer	May 22 '26	Proposed Sale	24.68	9,430	232,732		May 22 06:26 PM
Taich Adam	Officer	May 22 '26	Proposed Sale	24.68	11,779	290,706		May 22 05:40 PM
Saxonov Serge	Chief Executive Officer	Apr 14 '26	Sale	24.56	5,000	122,784	1,167,273	Apr 16 04:07 PM
Saxonov Serge	Chief Executive Officer	Mar 23 '26	Sale	19.13	10,000	191,297	1,177,273	Mar 25 05:15 PM
Saxonov Serge	Chief Executive Officer	Mar 24 '26	Sale	19.52	5,000	97,612	1,172,273	Mar 25 05:15 PM
Saxonov Serge	Chief Executive Officer	Mar 02 '26	Sale	22.73	16,152	367,097	1,203,667	Mar 04 04:14 PM
Serge Saxonov	Director, CEO	Mar 02 '26	Proposed Sale	22.13	41,152	910,694		Mar 02 04:21 PM
Teichmann Sarah A.	Director	Feb 25 '26	Sale	19.41	7,579	147,108	26,780	Feb 27 04:01 PM
Saxonov Serge	Chief Executive Officer	Feb 23 '26	Sale	18.58	9,632	178,928	1,061,924	Feb 25 04:52 PM
Taich Adam	Chief Financial Officer	Feb 23 '26	Sale	18.58	8,968	166,593	288,417	Feb 25 04:51 PM
Hindson Benjamin J.	See Remarks	Feb 23 '26	Sale	18.58	7,826	145,379	424,779	Feb 25 04:51 PM
SARAH A POLONIUS-TEICHMANN	Director	Feb 25 '26	Proposed Sale	19.41	7,579	147,108		Feb 25 04:44 PM
Hindson Benjamin J.	Officer	Feb 23 '26	Proposed Sale	19.19	8,301	159,269		Feb 23 05:30 PM
Saxonov Serge	Officer	Feb 23 '26	Proposed Sale	19.19	10,129	194,376		Feb 23 05:15 PM
Taich Adam	Officer	Feb 23 '26	Proposed Sale	19.19	9,188	176,318		Feb 23 05:00 PM
Saxonov Serge	Chief Executive Officer	Jan 05 '26	Option Exercise	1.20	50,000	60,000	1,071,556	Jan 07 04:52 PM
Taich Adam	Chief Financial Officer	Nov 24 '25	Sale	19.00	11,888	225,852	297,385	Nov 25 05:24 PM
Hindson Benjamin J.	See Remarks	Nov 24 '25	Sale	19.00	8,283	157,363	432,605	Nov 25 05:24 PM
Saxonov Serge	Chief Executive Officer	Nov 24 '25	Sale	19.00	13,261	251,936	1,021,556	Nov 25 05:23 PM
Hindson Benjamin J.	Officer	Nov 24 '25	Proposed Sale	18.34	7,392	135,569		Nov 24 05:32 PM
Saxonov Serge	Officer	Nov 24 '25	Proposed Sale	18.34	13,096	240,181		Nov 24 04:56 PM
Taich Adam	Officer	Nov 24 '25	Proposed Sale	18.34	11,312	207,462		Nov 24 04:28 PM
Saxonov Serge	Chief Executive Officer	Aug 22 '25	Sale	13.79	9,348	128,881	945,892	Aug 26 04:15 PM
Taich Adam	Chief Financial Officer	Aug 22 '25	Sale	13.79	22,315	307,657	309,273	Aug 26 04:14 PM
Hindson Benjamin J.	See Remarks	Aug 22 '25	Sale	13.79	7,486	103,209	440,888	Aug 26 04:12 PM
Saxonov Serge	Officer	Aug 22 '25	Proposed Sale	13.41	9,228	123,747		Aug 22 04:26 PM
Hindson Benjamin J.	Officer	Aug 22 '25	Proposed Sale	13.41	7,393	99,140		Aug 22 04:21 PM
Taich Adam	Officer	Aug 22 '25	Proposed Sale	13.41	22,037	295,516		Aug 22 04:17 PM

Open in Screener

RARE

Ultragenyx Pharmaceutical Inc

Jun 18 • 04:00PM ET

27.44

+0.53 1.97 %

Healthcare • Biotechnology • USA • Mid • NASD

RARE Ultragenyx Pharmaceutical Inc daily Stock Chart

Peers: BMRN RYTM KRYS MIRM PTCT IONS ALNY INCY VRTX KOD

| Held by: XBI VTI VB VBK VXF IBB IWP SCHA IWR IWF

Index	-	P/E	-	EPS (ttm)	-6.11	Insider Own	8.96%	Shs Outstand	98.00M	Perf Week	14.43%
Market Cap	2.70B	Forward P/E	-	EPS next Y	-0.70	Insider Trans	-1.58%	Shs Float	89.67M	Perf Month	22.23%
Enterprise Value	3.49B	PEG	-	EPS next Q	-1.22	Inst Own	97.72%	Short Float	16.40%	Perf Quarter	34.38%
Income	-609.36M	P/S	4.04	EPS this Y	23.11%	Inst Trans	4.73%	Short Ratio	7.95	Perf Half Y	-20.09%
Sales	669.43M	P/B	-	EPS next Y	84.40%	ROA	-46.73%	Short Interest	14.70M	Perf YTD	19.30%
Book/sh	-2.41	P/C	6.42	EPS next 5Y	-	ROE	-656.54%	52W High	42.37 -35.24%	Perf Year	-26.53%
Cash/sh	4.27	P/FCF	-	EPS past 3/5Y	16.78% -13.72%	ROIC	-68.31%	52W Low	18.29 50.03%	Perf 3Y	-43.16%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	22.81% 19.95%	Gross Margin	78.49%	Volatility	5.20% 4.88%	Perf 5Y	-71.09%
Dividend TTM	-	EV/Sales	5.21	EPS Y/Y TTM	-3.82%	Oper. Margin	-83.92%	ATR (14)	1.27	Perf 10Y	-50.10%
Dividend Ex-Date	-	Quick Ratio	1.85	Sales Y/Y TTM	13.33%	Profit Margin	-91.03%	RSI (14)	66.71	Recom	1.32
Dividend Gr. 3/5Y	- -	Current Ratio	2.02	EPS Q/Q	-17.21%	SMA20	15.94%	Beta	0.34	Target Price	52.05
Payout	-	Debt/Eq	-	Sales Q/Q	-2.36%	SMA50	12.83%	Rel Volume	1.93	Prev Close	26.91
Employees	1371	LT Debt/Eq	-	Earnings	May 05 AMC	SMA200	1.51%	Avg Volume	1.85M	Price	27.44
IPO	Jan 31, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	-23.67% -14.03%	Trades		Volume	3,562,375	Change	1.97%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-24-26	Downgrade	Goldman	Buy → Neutral	$25
Oct-20-25	Initiated	Wells Fargo	Overweight	$65
Jul-28-25	Resumed	H.C. Wainwright	Buy	$80
May-28-25	Initiated	William Blair	Outperform
Jun-06-24	Upgrade	Goldman	Neutral → Buy	$56 → $67
Apr-22-24	Initiated	RBC Capital Mkts	Outperform	$77
Dec-08-23	Initiated	Wells Fargo	Overweight	$72
Jun-14-23	Resumed	Credit Suisse	Outperform	$96
Jun-06-23	Upgrade	Evercore ISI	In-line → Outperform	$60 → $80
Apr-26-23	Initiated	Cantor Fitzgerald	Overweight	$114
Jan-18-23	Resumed	Canaccord Genuity	Buy	$90
Dec-30-22	Resumed	H.C. Wainwright	Buy	$82
Nov-03-22	Upgrade	Robert W. Baird	Neutral → Outperform	$50
Oct-13-22	Upgrade	Guggenheim	Neutral → Buy	$50
Aug-01-22	Downgrade	Evercore ISI	Outperform → In-line	$95 → $60
Mar-16-22	Upgrade	Credit Suisse	Neutral → Outperform	$99 → $105
Feb-11-22	Upgrade	JP Morgan	Neutral → Overweight	$132
Sep-30-21	Initiated	H.C. Wainwright	Buy	$106
Aug-19-21	Initiated	UBS	Sell	$73
Jul-15-21	Initiated	Guggenheim	Neutral

Show Previous Ratings

Jun-03-26 04:30PM	Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference (GlobeNewswire)
May-22-26 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-06-26 04:30PM	Ultragenyx to Participate at Bank of America's 2026 Healthcare Conference (GlobeNewswire)
08:30AM	Ultragenyx Pharmaceutical Inc. Q1 2026 Earnings Call Summary (Moby)
May-05-26 04:07PM	Ultragenyx: Q1 Earnings Snapshot (Associated Press)
04:01PM	Loading…
04:01PM	Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update (GlobeNewswire)
Apr-29-26 08:00AM	Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update (GlobeNewswire)
Apr-24-26 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-02-26 08:30AM	Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) (GlobeNewswire)
Mar-30-26 08:30AM	Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy (GlobeNewswire)
03:41AM	Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE (PR Newswire)
Mar-24-26 09:36AM	Microsoft reinstated, Ralph Lauren upgraded: Wall Street's top analyst calls (The Fly) -8.73%
Mar-20-26 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-13-26 06:17AM	Evotec, Vistagen lay off staff; Immutep shares collapse on study failure (BioPharma Dive)
Mar-12-26 08:30AM	Ultragenyx Announces Positive 36-Week Data from Phase 3 Study of DTX301 AAV8 Gene Therapy for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency (GlobeNewswire)
04:18AM	Loading…
04:18AM	Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE (PR Newswire)
Mar-11-26 09:00AM	LEVI & KORSINSKY, LLP: CEO AND CMO NAMED AS CONTROL PERSON DEFENDANTS IN ULTRAGENYX PHARMACEUTICAL SECURITIES ACTION (PR Newswire)
Mar-04-26 09:00AM	LEVI & KORSINSKY, LLP: RARE STOCK DECLINED OVER 42% FOLLOWING PHASE III STUDY FAILURE DISCLOSURE (PR Newswire)
Feb-25-26 09:00AM	LEVI & KORSINSKY, LLP: MANAGEMENT CONFIDENCE REPRESENTATIONS CHALLENGED IN ULTRAGENYX PHARMACEUTICAL SECURITIES ACTION (PR Newswire)
Feb-24-26 10:19AM	Ultragenyx Pharmaceutical Inc. (RARE): A Bull Case Theory (Insider Monkey)
Feb-23-26 04:30PM	Ultragenyx to Participate at Investor Conferences in March (GlobeNewswire)
08:30AM	Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa) (GlobeNewswire)
Feb-20-26 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-16-26 12:23PM	Strong Rare Disease Pipeline Drives Favorable Sentiment for Ultragenyx (RARE) (Insider Monkey)
Feb-14-26 01:29AM	Ultragenyx (RARE) Announces Positive Long-Term Clinical Data for UX111 Gene Therapy in Sanfilippo Syndrome Type A (Insider Monkey)
Feb-13-26 01:21PM	Why Is Ultragenyx Stock Sinking Friday? (Benzinga) -12.68%
10:23AM	Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y (Zacks)
08:30AM	Ultragenyx Pharmaceutical Inc. Q4 2025 Earnings Call Summary (Moby)
05:08AM	Ultragenyx cuts jobs as it seeks path to profit in 2027 (BioPharma Dive)
12:02AM	Ultragenyx Pharmaceutical Inc (RARE) Q4 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
08:14PM	Loading…
Feb-12-26 08:14PM	Ultragenyx Pharmaceutical Q4 Earnings Call Highlights (MarketBeat)
06:00PM	Ultragenyx (RARE) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
05:15PM	Ultragenyx (RARE) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
04:18PM	Ultragenyx: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update (GlobeNewswire)
Feb-09-26 03:30AM	Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE (PR Newswire)
Feb-07-26 03:33AM	Ultragenyx Pharmaceutical (RARE) Resubmits Biologics License Application for Gene Therapy Treatment (Insider Monkey)
Feb-06-26 07:40AM	Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights RARE (Business Wire)
Feb-05-26 04:05PM	Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update (GlobeNewswire)
10:00AM	Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks)
Feb-03-26 12:58PM	Ultragenyx Says Gene Therapy Shows Lasting Benefits, Slows Brain Decline In Fatal Childhood Disorder (Benzinga)
08:00AM	Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA) (GlobeNewswire)
Feb-02-26 11:03AM	Ultragenyx Pharmaceutical Resubmits UX111 BLA for Sanfilippo Syndrome (Zacks)
Jan-30-26 08:30AM	Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA (GlobeNewswire)
Jan-23-26 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
02:05PM	Ultragenyx Stock Declines After Missing Primary Endpoints on its Phase III Orbit and Cosmic Studies (PR Newswire)
Jan-21-26 04:58PM	Cathie Wood Has 13 Big Ideas For 2026: Here's The Ark Invest List And Stocks To Watch (Benzinga)
Jan-12-26 10:11AM	Morgan Stanley Trims Ultragenyx (RARE) PT to $50 While Betting on 2026 Biotech Recovery (Insider Monkey) +8.26%
07:30AM	Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference (GlobeNewswire)
Jan-09-26 03:16AM	Analysts Lower Ultragenyx (RARE) Target but Stay Bullish (Insider Monkey)
Jan-07-26 04:05PM	Ultragenyx to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +7.36%
Jan-05-26 03:56AM	Novo launches Wegovy pill; Argenx to swap CEOs (BioPharma Dive)
Dec-31-25 09:50AM	RARE Rises on Completion of Rolling Submission for AAV Gene Therapy (Zacks)
09:40AM	DigitalBridge downgraded, Commvault initiated: Wall Streets top analyst calls (TipRanks)
09:01AM	Ultragenyx (RARE) Moves 15.5% Higher: Will This Strength Last? (Zacks)
07:37AM	Ultragenyx (RARE) Rockets 15.5% on Bargain-Hunting After Steep Fall (Insider Monkey)
Dec-30-25 04:31PM	Stocks Fall Slightly in Thin Holiday Trade (Barchart) +15.52%
04:05PM	Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa) (GlobeNewswire)
03:58PM	Why Ultragenyx Pharmaceutical Stock Is Bouncing Back Today (Motley Fool)
12:39PM	Why Ultragenyx Stock Dropped 42% and What Comes Next (Barrons.com)
11:06AM	Stocks Slip as Bond Yields Rise (Barchart)
11:00AM	RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary Endpoint (Zacks)
09:36AM	DigitalBridge downgraded, Commvault initiated: Wall Street's top analyst calls (The Fly)
08:11AM	Company News for Dec 30, 2025 (Zacks)
06:17AM	S&P Futures Tread Water Ahead of FOMC Meeting Minutes (Barchart)
Dec-29-25 04:21PM	These Stocks Moved the Most Today: Nvidia, Tesla, Newmont, DigitalBridge, Praxis Precision, Ultragenyx, and More (Barrons.com) -42.32%
03:34PM	Why Ultragenyx Pharmaceuticals Stock Is Plummeting Today (Motley Fool)
01:18PM	These Stocks Are Moving the Most Today: Nvidia, Tesla, Newmont, DigitalBridge, Praxis Precision, Ultragenyx, and More (Barrons.com)
01:05PM	These biotech stocks are getting hammered by shocking brittle-bone treatment study results (MarketWatch)
08:30AM	Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta (GlobeNewswire)
Dec-19-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-11-25 07:44AM	Is Ultragenyx Pharmaceutical Inc. (RARE) One of the Best Biotech Stocks to Buy According to Wall Street Analysts? (Insider Monkey)
Dec-04-25 11:30AM	Ultragenyx (RARE) Up 14.4% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-28-25 11:57AM	Barclays Remains Cautious on Ultragenyx (RARE), Cites Setrusumab Study Analysis Despite 70% Positive Result Outlook (Insider Monkey)
Nov-24-25 04:30PM	Ultragenyx to Participate in Investor Conferences in December (GlobeNewswire)
Nov-21-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.73%
Nov-10-25 08:19PM	Morgan Stanley Reaffirms "Buy" Rating on Ultragenyx Pharmaceutical (RARE) with $55 PT (Insider Monkey)
Nov-05-25 10:48AM	Ultragenyx Q3 Earnings and Sales Miss Estimates, Increase Y/Y (Zacks)
12:10AM	Ultragenyx Pharmaceutical Inc (RARE) Q3 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
Nov-04-25 05:30PM	Here's What Key Metrics Tell Us About Ultragenyx (RARE) Q3 Earnings (Zacks)
05:15PM	Ultragenyx (RARE) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:13PM	Ultragenyx: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Ultragenyx Reports Third Quarter 2025 Financial Results and Corporate Update (GlobeNewswire)
04:01PM	Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita (burosumab) for $400 Million to OMERS Life Sciences (GlobeNewswire)
Oct-30-25 08:00AM	Ultragenyx Announces First Patient Dosed in Aurora Study Evaluating GTX-102 in Additional Angelman Syndrome Genotypes and Age Groups (GlobeNewswire)
Oct-29-25 10:00AM	Geron (GERN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Oct-28-25 04:30PM	Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update (GlobeNewswire)
10:00AM	Will Ultragenyx (RARE) Report Negative Q3 Earnings? What You Should Know (Zacks)
Oct-24-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.31%
Oct-17-25 09:16AM	Strength Seen in DBV Technologies (DBVT): Can Its 6.8% Jump Turn into More Strength? (Zacks)
Oct-08-25 12:57AM	Bank of America Securities Remains Bullish on Ultragenyx Pharmaceutical (RARE) (Insider Monkey)
Oct-03-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-02-25 09:45AM	Assenagon Boosts Ultragenyx Pharmaceutical Inc. (RARE) Stake by 439% Amid Breakthrough Pipeline (Insider Monkey)
Sep-30-25 04:05PM	Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President (GlobeNewswire)
04:00AM	Cantor Fitzgerald Reiterates a Buy Rating on Ultragenyx Pharmaceutical (RARE) (Insider Monkey)
Sep-29-25 08:28AM	FDA Approves Label Extension of REGN's Cholesterol Drug Evkeeza (Zacks)
Sep-19-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-16-25 09:17AM	Is Ultragenyx Pharmaceutical (RARE) a Compelling Long-Term Opportunity? (Insider Monkey)
Sep-10-25 11:11AM	IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome (Zacks)
Sep-09-25 11:12AM	RARE Reports Positive Long-Term Data From Metabolic Disorder Study (Zacks)

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ph.D.Dr. Emil D. Kakkis M.D.

Executive VP of Corporate Strategy & CFOMr. Howard Horn

Chief Legal Officer & Executive VP of Corporate AffairsMs. Karah Herdman Parschauer J.D.

Executive VP & Chief Commercial OfficerMr. Erik Harris M.B.A.

Chief Medical Officer & Executive VPDr. Eric Crombez M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sanders Corazon (Corsee) D.	Director	Jun 15 '26	Sale	25.05	2,000	50,100	21,095	Jun 15 06:50 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Jun 15 '26	Sale	24.62	1,899	46,753	94,462	Jun 15 06:46 PM
KARAH PARSCHAUER	Officer	Jun 15 '26	Proposed Sale	24.35	3,799	92,506		Jun 15 04:50 PM
CORAZON D. SANDERS	Director	Jun 15 '26	Proposed Sale	25.05	2,000	50,100		Jun 15 04:12 PM
Horn Howard	Chief Financial Officer	Jun 01 '26	Sale	23.77	4,653	110,602	105,689	Jun 01 07:11 PM
HOWARD HORN	Officer	Jun 01 '26	Proposed Sale	23.77	4,653	110,602		Jun 01 04:08 PM
SULIMAN SHEHNAAZ	Director	May 18 '26	Sale	25.12	5,740	144,189	27,951	May 18 06:41 PM
SHEHNAAZ SULIMAN	Director	May 18 '26	Proposed Sale	25.12	5,740	144,189		May 18 04:50 PM
Crombez Eric	EVP and Chief Medical Officer	May 05 '26	Sale	24.96	344	8,586	111,189	May 06 02:51 PM
Horn Howard	Chief Financial Officer	May 01 '26	Sale	24.90	4,683	116,607	110,342	May 04 05:35 PM
HOWARD HORN	Officer	May 01 '26	Proposed Sale	24.90	4,683	116,607		May 01 04:06 PM
Horn Howard	Chief Financial Officer	Apr 01 '26	Sale	20.97	4,683	98,203	80,351	Apr 02 06:19 PM
HOWARD HORN	Officer	Apr 01 '26	Proposed Sale	20.97	4,683	98,203		Apr 01 04:12 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Mar 06 '26	Sale	21.40	6,018	128,785	70,328	Mar 10 04:51 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Mar 10 '26	Sale	22.67	3,508	79,526	66,820	Mar 10 04:51 PM
KARAH PARSCHAUER	Officer	Mar 10 '26	Proposed Sale	22.67	3,508	79,526		Mar 10 04:42 PM
KARAH PARSCHAUER	Officer	Mar 06 '26	Proposed Sale	21.40	6,018	128,775		Mar 06 05:28 PM
Pinion John Richard	See Remarks	Mar 02 '26	Sale	22.80	10,029	228,661	110,026	Mar 03 07:09 PM
Harris Erik	EVP & Chief Commercial Officer	Mar 02 '26	Sale	22.80	10,539	240,289	89,515	Mar 03 07:08 PM
KAKKIS EMIL D	President & CEO	Mar 02 '26	Sale	22.80	54,404	1,240,411	658,994	Mar 03 07:06 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Mar 02 '26	Sale	22.80	8,135	185,478	76,346	Mar 03 06:51 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Mar 02 '26	Sale	22.80	1,632	37,210	48,670	Mar 03 06:51 PM
Horn Howard	Chief Financial Officer	Mar 02 '26	Sale	22.70	8,409	190,914	86,669	Mar 03 06:50 PM
Horn Howard	Chief Financial Officer	Mar 03 '26	Sale	22.40	1,635	36,624	85,034	Mar 03 06:50 PM
Crombez Eric	EVP and Chief Medical Officer	Mar 02 '26	Sale	22.80	7,029	160,261	76,301	Mar 03 06:49 PM
HOWARD HORN	Officer	Mar 03 '26	Proposed Sale	22.40	1,635	36,624		Mar 03 04:41 PM
HOWARD HORN	Officer	Mar 02 '26	Proposed Sale	22.54	3,119	70,302		Mar 02 05:08 PM
Horn Howard	Chief Financial Officer	Feb 02 '26	Sale	23.56	3,061	72,117	88,935	Feb 03 12:00 PM
HOWARD HORN	Officer	Feb 02 '26	Proposed Sale	23.56	3,061	72,117		Feb 02 04:09 PM
Horn Howard	Chief Financial Officer	Jan 02 '26	Sale	22.84	3,150	71,946	91,996	Jan 05 04:07 PM
HOWARD HORN	Officer	Jan 02 '26	Proposed Sale	22.84	3,150	71,946		Jan 02 04:10 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Dec 29 '25	Sale	34.38	85	2,922	50,450	Dec 30 01:49 PM
Horn Howard	Chief Financial Officer	Dec 10 '25	Sale	36.38	3,081	112,087	95,146	Dec 11 12:10 PM
HOWARD HORN	Officer	Dec 10 '25	Proposed Sale	36.38	3,081	112,087		Dec 10 04:05 PM
Horn Howard	Chief Financial Officer	Oct 13 '25	Sale	31.51	7,942	250,252	98,227	Oct 14 12:15 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Sep 18 '25	Sale	29.17	64	1,867	50,242	Sep 19 06:23 PM
KARAH PARSCHAUER	Officer	Sep 12 '25	Proposed Sale	31.17	2,450	76,366		Sep 12 04:17 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Sep 12 '25	Sale	31.17	2,450	76,366	73,271	Sep 12 04:11 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Sep 05 '25	Sale	31.39	84	2,637	50,306	Sep 08 02:01 PM
Sanders Corazon (Corsee) D.	Director	Jun 20 '25	Sale	37.39	2,405	89,923	15,344	Jun 23 01:50 PM
CORAZON D. SANDERS	Director	Jun 20 '25	Proposed Sale	37.39	2,405	89,923		Jun 20 04:02 PM

TXG

10x Genomics Inc

RARE

Ultragenyx Pharmaceutical Inc

Upgrade your Finviz experience